Scancell Share Discussion Threads

[miavoce] 05/12/2024 16:19

Hi Bermudashorts - maybe the introduction of cohort 4 (for which they must have high expectations) prompted the need for more funding in the short term. I would have expected them to announce the addition of the new cohort - strange that they didn't. Maybe we'll get something shortly.

Perhaps they couldn't announce the fundraise at 8am because it was an accelerated book-build and maybe the brokers involved simply weren't ready to start at 8am. Just guessing.

Anyway there will be reasons why it happened like it did - maybe time will reveal them (particularly if a number of shareholders have expressed their discontent directly to the board).

[inanaco] 05/12/2024 16:14

Data changes things .. Bermuda and so does Politics, dramatically with the Grubby Socialists in power

but don't worry the speech today will save the UK .... apparently

[bermudashorts] 05/12/2024 16:07

miavoce

...........but we were told they were fully funded until August 2025 and had funds to take us beyond SCIB1/iSCIB1+ and Modi1 read outs. For whatever reason (I'm sure we'll come back to that at some stage) they needed to raise now and when they issued that Genmbab RNS yesterday, they knew full well they would be raising at 10.5p. They could and should have released both RNSs at the same time.

[inanaco] 05/12/2024 16:06

i will just remind you of CTl-4 impact on CD4 T cells

Yes, CTLA-4 has a significant impact on CD4 T cells:


CTLA-4 expression
CTLA-4 is a cell surface molecule that's highly expressed on CD4+ T cells and other immune cells. CTLA-4 expression in CD4+ T cells suppresses their proliferation.
CTLA-4 deficiency
When CTLA-4 is absent, the magnitude and frequency of peptide-specific CD4+ T cell responses increases.
CTLA-4 blockade
Blocking CTLA-4 allows T cells to be primed and activated, which can unleash the body's anti-tumor T-cell response. In cancer patients, CTLA-4 blockade can cause a subpopulation of CD4 T cells to expand in the blood and tumor. These cells express high levels of ICOS and secrete IFNγ, a cytokine that plays a role in antitumor responses.
CTLA-4 function
CTLA-4 proteins contribute to the suppressor function of regulatory T cells (Tregs). CTLA-4 proteins are localized in Tregs in submembrane vesicles, but in naive Tconv cells they're retained in Golgi vesicles. TCR signaling of Tconv cells releases CTLA-4 proteins from Golgi retention, causing activated Tconv cells to acquire suppressor function.
CTLA-4 blockade increases IFNγ-producing CD4 + ... - PNAS
30 Sept 2008 — These data indicate that a major impact of CTLA-4 blockade in cancer patients was the expansion, both within the blood...

PNAS
CTLA-4 - an overview | ScienceDirect Topics
CTLA-4 is a cell surface molecule that is heavily involved in the down-regulation of T-cell activation [11]. It is strongly expres...

ScienceDirect.com
Differential CTLA-4 expression in human CD4+ versus CD8+ ...
Finally, we demonstrate that the CD4+ bias in CTLA-4 expression affects CD4+ T cells by preferential suppression of CD4+ prolifera...
National Institutes of Health (NIH) (.gov)
Show all
Generative AI is experimental.
Increased CTLA-4 on CD4+ T cells restricts CD4+ T cell proliferation. Anti-CTLA-4 has been shown to block interaction between B7 and CTLA-4, thereby removing inhibitory regulation of signaling. To determine the functional significance of the differential expression of CTLA-4 on CD4+ vs.

[nigelpm] 05/12/2024 16:06

One benefit of the Genmab decision landing on the same day as the fundraise is that it must have increased support for the fundraise.

Correct. I've heard on good authority they had asked for more funding so perhaps they were ok getting less and it did indeed "encourage" the 8m to become 10m. Either way it's done, time to sit back and wait for the data and hope it's decent. Otherwise all bets are off anyway.

[miavoce] 05/12/2024 15:57

The fundraise would have been planned for yesterday a good while in advance. I suspect that they were taken by surprise by Genmab agreeing the deal so early in December and on the exact day of the fundraise, which was obviously outside Scancell's control.

Why didn't Scancell plan their fundraise for Jan, by which time the Genmab decision would have been known ? Well, imagine if Genmab had decided not to progress with the deal, what price do you think the fundraise would have achieved then ?

Ultimately Scancell had to decide whether to do the fundraise before or after the Genmab decision, and they went for the safe option to do it before. Unfortunately they then got caught out by Genmab making their decision at the same time as the fundraise.

All IMO but makes perfect sense when you look back at what happened.

One benefit of the Genmab decision landing on the same day as the fundraise is that it must have increased support for the fundraise.

[inanaco] 05/12/2024 15:52

answer is The 43 patient cohort 4 testing the intradermal approach

with that number of patients treated at 120 you can get a great deal without the registrational trials data, its way to many to "Fluke" which means Scancell has a Deal possibly by end of 2025

why do that you may ask ...

Simon stage 1 on Modi1 19 patients

what happens if that has the possibility of going to a registrational trial to ?

the consequences of that vaccine approval dwarfs ISCIB1

[nigelpm] 05/12/2024 15:48

I think you are all missing the point. You don't decide to do a placing and then launch the same day. That had been in the offering for weeks - maybe even started back in October given the c.9/10 months before running out of cash.

The separate commercial RNS has to be released once done.

[plasybryn] 05/12/2024 15:36

Cash runway to H2 2026 is reassuring.

Over subscribed is positive. Not surprised at such a give-away price.

Redmile & Vulpes subscribed to 36m between them, which is supportive, but entirely understandable. They don't want to be diluted.

Seth Nirmalananthan Director & CFO bought 190,476 shares. Good on him, but what about other directors?

But I still don't understand what possessed them to announce strong news in the morning driving the share price to 15p only to after hours do a 10.5p placement. Who advised them to do that? Panmure Librum? Not a clever move in terms of respect and trust? As the money wasn't needed urgently, why was it done in such a fashion? Makes no sense. Was it to satisfy demand from some Institutions for a few cheap shares they didn't want to buy in the market?
I hope at some point they answer how they could make such a crass decision.

[inanaco] 05/12/2024 15:29

whats your question ? i can probably answer it, if not i can email it on your behave

[inanaco] 05/12/2024 15:28

No use scancell email address

[plasybryn] 05/12/2024 15:25

Is Lindy Durrant still Professor of Cancer Immunotherapy at the The University of Nottingham, Therapeutic Antibody Centre (NUTAC) because my email to her has been returned?

[nigelpm] 05/12/2024 15:21

MT - he's not going to do that - he'll get plenty of options.

[2tyke] 05/12/2024 13:55

Yes very very risky ..
Just don't ask inane about risk.
He's hopeless.
Who's Phil ?

[markingtime] 05/12/2024 13:43

I'd like to see Phil buy a chunk of shares in the market, when the open offer has closed - and before the next close period starts.

[echelon] 05/12/2024 12:45

Given the risks associated with this serial disappointer a safer strategy might be to buy a few when it goes sub 10p assuming you can wait a few months before the next hype spike.

[2tyke] 05/12/2024 12:37

Markingtime has the best idea....load up on Bitcoin....sit back...and relax !!
😂

[the real lozan] 05/12/2024 12:36

"Lozan you are the only one I feel bad for banning.

But you speak with honesty and you are right to be proud of that."
.
Under 'normal' CONditions...I may respond
However
Given that these forums... especially this one... are based in a 'misleading and somewhat deceitful manner',perpetrated by ONE source / group in particular,,,
Folks might forgive me if I remain a tad 'reluctant' to react.
A SAD, but true realisation of what 'path' this / these SCLP forums have been led down.
No offence intended

[2tyke] 05/12/2024 12:32

No Nigel....it isn't onwards and upwards I'm afraid.
Have I ever been wrong on SP's here ?
Have you or others on here ever been right about SP's ?

[octopus100] 05/12/2024 12:24

Well company good for next 2 years now without doing any deals means if things come along they are able to negotiate.

[chilltime] 05/12/2024 10:33

Good attitude Nigel.

It’s certainly not a case of wholesale forward selling, that some suffer, the volumes required and retail masses are simply not in Scancell to support that city game.

The one plus is if any typical regular irresponsible spread betters (beyond their means) were in, then they got a butt kicking today and it removes them for the time being.

That said with volumes very low, perhaps there were none.

[markingtime] 05/12/2024 10:32

Strange that Noah is on the up.....perhaps people are expecting floods?

[inanaco] 05/12/2024 10:27

Muhammad overtakes Noah as top baby boy name
Name was second most popular for boys in 2022 and has been in the top 10 since 2016

Telegraph Reporters
Related Topics
Office for National Statistics
05 December 2024 9:54am GMT

Muhammad replaced Noah as the most popular name for baby boys in England and Wales in 2023, new data from the Office for National Statistics have revealed.

Noah came in second with Oliver third.

Muhammad was the second most popular boys’ name in 2022 and has been in the top 10 since 2016.

Olivia remained the most popular name for baby girls for the eighth year in a row, with Amelia and Isla the second and third most popular for girls.

[nigelpm] 05/12/2024 10:25

I'd say it's a good sign the price dropped to placing price (as it would) but is now starting to head the right way with some lumpy trades. Onwards and upwards.

As a shareholder I'm irritated but time to move on and await the expected data.

[chilltime] 05/12/2024 09:58

Investor

I don’t see myself as a true investor in Scancell as I have never provided cash for the company via any raise. All I’ve done is purchase shares in the market. So I don’t feel I can moan about decisions.

Anyone that has provided cash via a raise, is/was a true investor.

Those that don’t are simply trading the market be it weeks, months or years.

Clearly some internal decisions made on boxes they want ticked and hence the raise.

More cash will arrive in the coming months for Glymab deals extending the cash runway probably into 2027.

Stuck record I know on SC134 but that’s the one that could see a substantial deal.

In the rehashed plan there is no mention of taking SC134 into phase 1.
Lindy wanted that into phase 1 to add zeros to a deal. I guess the current talks are of sufficient indications (at this time) to licence it out. But now they are under no pressure on timing re that deal. Depending on offer levels, they can in the future take it into phase 1, no cheap deals etc.

The cost of phase 1 is minimal in comparison to a deal cost post a successful phase 1. The target is very low expression on limited healthy tissues, efficacy and very low toxicity potential are the attractive points.